Download App

Log in to access Online Inquiry
Company Overview More
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with a Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
CEO: Emalfarb, Mark A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

DYAI Dyadic
2.140+0.010+0.47%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
-43.3% 15.44M -30.36% 20.26M -30.36% 20.26M -25.19% 22.75M
-Cash and cash equivalents
-4.88% 12.42M -23.69% 15.75M -23.69% 15.75M -37.52% 13.66M
-Short-term investments
-78.69% 3.02M -46.65% 4.51M -46.65% 4.51M 6.35% 9.09M
Receivables
2.74% 557.05K -8.42% 372.21K -8.42% 372.21K -72.14% 254.43K
-Accounts receivable
19.64% 350.94K -22.49% 101.18K -22.49% 101.18K -92.64% 46.99K
-Accrued interest receivable
-81.62% 28.89K -15.92% 94.38K -15.92% 94.38K -29.71% 74.79K
-Other receivables
93.38% 177.21K 7.94% 176.66K 7.94% 176.66K -21.29% 132.64K
Prepaid assets
12.94% 244.17K 33.96% 375.83K 33.96% 375.83K 35.87% 569.97K
Total current assets
-41.98% 16.24M -29.46% 21.01M -29.46% 21.01M -25.73% 23.57M
Non current assets
Investments and advances
701.81% 2.28M 0% 284.71K 0% 284.71K -- 284.71K
Other non current assets
-0.76% 6.1K -1.73% 6.12K -1.73% 6.12K 10.53% 6.14K
Total non current assets
686.95% 2.29M -0.04% 290.83K -0.04% 290.83K 5133.03% 290.85K
Total assets
-34.48% 18.53M -29.17% 21.3M -29.17% 21.3M -24.83% 23.86M
Liabilities
Current liabilities
Payables
-41.22% 866.32K 52.79% 1.55M 52.79% 1.55M -1.94% 957.8K
-accounts payable
-41.22% 866.32K 52.79% 1.55M 52.79% 1.55M -1.94% 957.8K
Current accrued expenses
91.96% 533.01K 44.88% 709.56K 44.88% 709.56K 35.74% 842.45K
Current deferred liabilities
-49.28% 427.15K 142.41% 298.21K 142.41% 298.21K 5.74% 162.68K
Current liabilities
-29.58% 1.83M 57.19% 2.56M 57.19% 2.56M 12.09% 1.96M
Non current liabilities
Non current deferred liabilities
-- 308.82K -- 352.94K -- 352.94K -- --
Total non current liabilities
-- 308.82K -- 352.94K -- 352.94K -- 0
Total liabilities
-17.67% 2.14M 78.9% 2.91M 78.9% 2.91M 12.09% 1.96M
Shareholders'equity
Share capital
1.78% 40.52K 1.85% 40.48K 1.85% 40.48K 1.5% 40.33K
-common stock
1.78% 40.52K 1.85% 40.48K 1.85% 40.48K 1.5% 40.33K
-Preferred stock
-- 0 -- 0 -- 0 -- 0
Retained earnings
-22.73% -66.24M -25.79% -63.75M -25.79% -63.75M -22.2% -59.53M
Paid-in capital
3.02% 101.52M 3.07% 101.03M 3.07% 101.03M 2.79% 100.32M
Less: Treasury stock
0% 18.93M 0% 18.93M 0% 18.93M 0% 18.93M
Total stockholders'equity
-36.18% 16.39M -35.35% 18.39M -35.35% 18.39M -26.99% 21.9M
Total equity
-36.18% 16.39M -35.35% 18.39M -35.35% 18.39M -26.99% 21.9M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%